康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENT
INSIDE INFORMATION RESEARCH FINDINGS OF PHASE I CLINICAL TRIAL FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR)
Monthly Return of Equity Issuer on Movements in Securities
CLARIFICATION ANNOUNCEMENT
INSIDE INFORMATION CLINICAL TRIAL APPLICATION APPROVAL IN CANADA FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR)
List of Directors and their Roles and Functions
INSIDE INFORMATION THE PROGRESS OF PROPOSED ISSUE OF A SHARES FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS
INSIDE INFORMATION COLLABORATION WITH NATIONAL RESEARCH COUNCIL OF CANADA TO ADVANCE CLINICAL TRIAL FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5) IN CANADA
POLL RESULTS OF THE 2019 ANNUAL GENERAL MEETING AND ELECTION OF THE BOARD OF DIRECTORS, THE BOARD OF SUPERVISORS AND THE COMMITTEES OF THE BOARD OF DIRECTORS
INSIDE INFORMATION ANNOUNCEMENT ON APPROVAL OF PROPOSED ISSUE OF A SHARES BY THE LISTING COMMITTEE FOR SCI-TECH INNOVATION BOARD

1 41 42 43 44 45 52